by Elana GotkineMore than 20% of children with two or more medication exposures experience major drug-drug interactions (DDIs) annually, according to a study published online Jan. 4 inPediatrics
by Elana GotkineMore than 20% of children with two or more medication exposures experience major drug-drug interactions (DDIs) annually, according to a study published online Jan. 4 inPediatrics
byCleveland ClinicPercentage of patients who were persistent with antiobesity medication (AOM) at early stage, medium term, and long term, by AOM agent. [Color figure can be viewed atwiley
byCleveland ClinicPercentage of patients who were persistent with antiobesity medication (AOM) at early stage, medium term, and long term, by AOM agent. [Color figure can be viewed atwiley
by Leslie Tate,Tulane UniversityThe study findings could pave the way for improved Lyme disease treatments, particularly in persistent cases, said lead researcher Monica Embers, PhD, associate p
by Leslie Tate,Tulane UniversityThe study findings could pave the way for improved Lyme disease treatments, particularly in persistent cases, said lead researcher Monica Embers, PhD, associate p
Olshansky says, "While more people may live to 100 or beyond this century, these cases will remain outliers and won't significantly raise the average lifespan."
Olshansky says, "While more people may live to 100 or beyond this century, these cases will remain outliers and won't significantly raise the average lifespan."
by Impact Journals LLCProgeroid syndrome overview. Credit: 2024 Worm et al.Progeroid disorders are a heterogenous group of rare and complex hereditary syndromes presenting with pleiotropic phenotypes
by Impact Journals LLCProgeroid syndrome overview. Credit: 2024 Worm et al.Progeroid disorders are a heterogenous group of rare and complex hereditary syndromes presenting with pleiotropic phenotypes
byUniversity of SharjahRepresentative images of immunohistochemical staining of DMB and DCC implantation sites to visualize the intensity distribution of osteogenic factors. Credit:PLOS ON
byUniversity of SharjahRepresentative images of immunohistochemical staining of DMB and DCC implantation sites to visualize the intensity distribution of osteogenic factors. Credit:PLOS ON
by University of SharjahAlbizia lebbeck—Shirish/Siris Tree. Credit: Wikimedia Commons,CC BY-SA 4.0Albizia lebbeck is the scientific name of the siris tree, which may hold the promise of wor
by University of SharjahAlbizia lebbeck—Shirish/Siris Tree. Credit: Wikimedia Commons,CC BY-SA 4.0Albizia lebbeck is the scientific name of the siris tree, which may hold the promise of wor
byUniversity of California, Los AngelesCredit: Pixabay/CC0 Public DomainA mutation in a protein regulating natural killer (NK) cells' function is at the root of immune deficiency in some peo
byUniversity of California, Los AngelesCredit: Pixabay/CC0 Public DomainA mutation in a protein regulating natural killer (NK) cells' function is at the root of immune deficiency in some peo
by Georgia Gowing,Macquarie UniversityDr. Alison Zhang. Credit: Macquarie UniversityAn international clinical trial of a treatment for advanced urothelial cancer has found a new dual therapy can
by Georgia Gowing,Macquarie UniversityDr. Alison Zhang. Credit: Macquarie UniversityAn international clinical trial of a treatment for advanced urothelial cancer has found a new dual therapy can
byJohns Hopkins University School of MedicineNeuronal membrane proteasomes are labeled with a red compound and appear in a subset of sensory neurons that are labeled with green compound. Note, n
byJohns Hopkins University School of MedicineNeuronal membrane proteasomes are labeled with a red compound and appear in a subset of sensory neurons that are labeled with green compound. Note, n
by Andrew Smith,Rutgers UniversityX-ray crystal structure of the covalent inhibitor Jun11313 with SARS-CoV-2 PLproand structure-based design of biarylphenyl SARS-CoV-2 PLproinhibitor
by Andrew Smith,Rutgers UniversityX-ray crystal structure of the covalent inhibitor Jun11313 with SARS-CoV-2 PLproand structure-based design of biarylphenyl SARS-CoV-2 PLproinhibitor